Item Type | Name |
Concept
|
Aminosalicylic Acid
|
Concept
|
Mesalamine
|
Academic Article
|
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
|
Academic Article
|
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group.
|
Academic Article
|
Evolving treatment strategies for inflammatory bowel disease.
|
Academic Article
|
A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
|
Academic Article
|
Comparative tolerability of treatments for inflammatory bowel disease.
|
Academic Article
|
Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis.
|
Academic Article
|
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.
|
Academic Article
|
Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis.
|
Academic Article
|
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
|
Academic Article
|
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
|
Academic Article
|
Mesalamine derivatives in the treatment of Crohn's disease.
|
Academic Article
|
Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.
|
Academic Article
|
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.
|
Academic Article
|
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.
|
Academic Article
|
Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt.
|
Academic Article
|
Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis.
|
Academic Article
|
Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis.
|
Academic Article
|
New lessons: classic treatments, expanding options in ulcerative colitis.
|
Academic Article
|
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
|
Academic Article
|
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
|
Academic Article
|
Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
|
Academic Article
|
Controversies with aminosalicylates in inflammatory bowel disease.
|
Academic Article
|
Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts.
|
Academic Article
|
Aminosalicylates: old and new.
|
Academic Article
|
Optimizing conventional therapies for inflammatory bowel disease.
|
Academic Article
|
Aminosalicylates for induction of remission or response in Crohn's disease.
|
Academic Article
|
Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis.
|
Academic Article
|
The case for using 5-aminosalicyclates in Crohn's disease: pro.
|
Academic Article
|
Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.
|
Academic Article
|
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
|
Academic Article
|
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
|
Academic Article
|
5-ASA enema therapy.
|
Academic Article
|
Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.
|
Academic Article
|
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
|
Academic Article
|
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
|
Academic Article
|
Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
|
Academic Article
|
Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid.
|
Academic Article
|
Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.
|
Academic Article
|
Medical therapy to reduce postoperative Crohn's disease recurrence.
|
Academic Article
|
The role of mesalazine in Crohn's disease.
|
Academic Article
|
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
|
Academic Article
|
Mea culpa.
|
Academic Article
|
Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
|
Academic Article
|
Comparing guidelines for the treatment of inflammatory bowel disease.
|
Academic Article
|
Oral or Topical 5-ASA in Ulcerative Colitis.
|
Academic Article
|
Aminosalicylates for induction of remission or response in Crohn's disease.
|
Academic Article
|
Too Soon to Discard 5-ASAs?
|
Academic Article
|
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
|
Academic Article
|
MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.
|